Takeda — Entyvio (vedolizumab)
Ulcerative Colitis · 8 items
Entyvio · UC · Takeda Press Release · June 2026
FDA has accepted Takeda's sBLA to expand IV Entyvio into pediatric UC and Crohn's disease (ages 2+), with PDUFA decision expected Q1 2027. If approved, Entyvio would be the only gut-selective biologic approved in this age range. For HEOR teams, this opens new modeling needs around pediatric cost-effectiveness and budget impact in a currently underserved population.
Entyvio · UC · Takeda Press Release · 2026
The KEPLER Phase 3 study showed 47.3% clinical remission at week 54 in pediatric UC/CD patients who had failed conventional therapy or anti-TNF, with safety consistent with the adult profile. This is the core clinical evidence supporting the sBLA; HEOR teams may be called on to model comparative efficacy and QoL impact versus off-label options currently used in children.
Entyvio · UC · DDW 2026 · AbbVie
AbbVie presented RWE at DDW 2026 showing UC/CD patients who switched to upadacitinib had 31% lower odds of hospitalization and 26% lower odds of ED visits compared to patients who escalated their existing biologic dose (retrospective US claims data, propensity score matching). This directly challenges Entyvio's positioning as an escalation anchor. Takeda may need updated RWE or network meta-analyses to rebut this.
Entyvio · UC · Eli Lilly · 2026
Lilly's LUCENT-3 OLE showed 63.5% of patients who achieved disease clearance at year 1 sustained it at year 4 (49.7% under modified non-responder imputation). Lilly describes Omvoh as the first and only IL-23p19 to demonstrate this durability in UC. During the 3-year extension, only 1 UC-related hospitalization and 0 UC-related surgeries occurred. This long-term differentiation claim warrants review of comparable Entyvio durability data.
Entyvio · UC · Intestinal Research · PubMed (PMID 42403091) · July 2026
This multicenter Chinese RWE study (n=239) reported vedolizumab steroid-free remission of 59.4% at week 52 declining to 40.3% by week 156, with anti-TNF-naive patients showing significantly better long-term persistence. The Asian RWE evidence base for vedolizumab remains sparse, making this dataset useful for regional submissions or payer discussions in Asia-Pacific markets.
Entyvio · UC · ECCO 2026 · Journal of Crohn's and Colitis · February 2026
The VERDICT trial presented at ECCO 2026 showed vedolizumab was associated with corticosteroid-free histologic remission rates that increased incrementally, reaching nearly two-thirds of patients by week 48. Histologic remission is increasingly accepted as a treatment target beyond clinical and endoscopic endpoints, and this data strengthens vedolizumab's mucosal healing story for HTA submissions in European markets where histology is gaining traction as an endpoint.
Entyvio · UC · ECCO 2026 (OP02) · February 2026
An RCT at ECCO 2026 evaluated vedolizumab combined with upadacitinib as an 8-week induction strategy in moderate-to-severe UC. Combination biologic therapy is an emerging frontier in IBD — this positions vedolizumab as a backbone partner rather than standalone option, which could complicate indirect comparisons and cost-effectiveness models but may also open new commercial angles for Takeda.
Entyvio · UC · Scandinavian Journal of Gastroenterology · PubMed (PMID 42405928) · July 2026
Harvard retrospective study found only 11.3% of real-world UC patients started on vedolizumab or ustekinumab would have met pivotal trial eligibility criteria, primarily due to prior biologic exposure and comorbidities. Key implication: pivotal trial efficacy data may not generalize to real-world patients — a core consideration when building cost-effectiveness models or responding to payer challenges about external validity.
Takeda — Oveporexton (TAK-861)
Narcolepsy Type 1 · 7 items · PDUFA Q3 2026
Oveporexton · Narcolepsy Type 1 · Takeda Press Release · February 2026
FDA accepted the NDA and granted Priority Review for oveporexton — a first-in-class oral OX2R-selective agonist for NT1 — with PDUFA action expected this quarter. If approved, this is the first orexin agonist on market, mechanistically distinct from sodium oxybate and pitolisant. HEOR teams should have clinical value frameworks, economic models, and payer-facing materials ready now.
Oveporexton · Narcolepsy Type 1 · SLEEP 2026 / Takeda Press Release · June 2026
Additional Phase 3 results presented at SLEEP 2026 (FirstLight n=168; RadiantLight n=105) showed oveporexton improved daily functioning, cognition, and nighttime sleep. On the FINI cognitive function domain, ~70% of treated patients reported no significant cognitive difficulties vs. ~15% in placebo. Functional impact (FINI) was statistically significant vs. placebo (p<0.001) across all doses at week 12. Nighttime sleep patterns shifted toward those observed in healthy controls.
Oveporexton · Narcolepsy Type 1 · FDA / Harmony Biosciences · February 2026
Harmony Biosciences received FDA approval for Wakix in pediatric narcolepsy cataplexy, supported by Phase 3 data published in The Lancet Neurology. While oveporexton targets adult NT1 initially, this pediatric expansion strengthens Wakix's franchise and sets a competitive precedent. Worth tracking whether Takeda has a pediatric oveporexton development plan.
Oveporexton · Narcolepsy Type 1 · Alkermes / FDA · January 2026
Alkermes received FDA Breakthrough Therapy designation for alixorexton (another OX2R agonist) for narcolepsy type 1 in January 2026, with a global Phase 3 program launching Q1 2026. This introduces a second next-generation orexin agonist into the pipeline alongside oveporexton, potentially fragmenting the market Takeda is targeting. HEOR teams should begin tracking alixorexton as a future comparator that will complicate payer negotiations and value dossiers for oveporexton.
Oveporexton · Narcolepsy Type 1 · ClinicalTrials.gov (NCT07363720) · January 2026
A new Phase 3 double-blind randomized withdrawal trial of oveporexton in narcolepsy type 1 (TAK-861-3003) began recruiting in January 2026, with primary completion estimated October 2026. Randomized withdrawal designs are the gold standard for demonstrating durability of effect and are increasingly required by payers to confirm sustained benefit — completion of this trial will further strengthen the evidence package for market access discussions globally.
Oveporexton · Narcolepsy Type 1 · Takeda Investor Relations · FY2025 Full Year Results
Takeda's FY2025 annual results confirmed oveporexton commercial launch planned for H2 2026 in the US following expected FDA approval, with regulatory filings also completed in Japan and China. This marks the transition from clinical to commercial phase — HEOR teams working on payer submissions, formulary access, and value dossiers for ex-US markets should be accelerating work now ahead of multi-market launches.
Oveporexton · Narcolepsy Type 1 · SLEEP 2026 / Jazz Pharmaceuticals · June 2026
Jazz presented 11 late-breaking abstracts at SLEEP 2026 for Xywav. Phase 4 XYLO data: patients switching from high-sodium oxybate reported improvements in sodium/fluid imbalance symptoms (edema, nocturia) and reductions in lipid biomarkers. DUET data: mean time to stable Xywav dose was 42.1 days (idiopathic hypersomnia) and 41.8 days (narcolepsy). REMS program data covered over 13,000 patients. This is Jazz defending market position ahead of the oveporexton launch and will create payer comparison benchmarks.
Kyowa Kirin — POTELIGEO (mogamulizumab)
Mycosis Fungoides / Sézary Syndrome · 5 items
POTELIGEO · MF/SS · GlobeNewswire / World Congress of Cutaneous Lymphoma · June 30, 2026
Kyowa Kirin presented two ITC analyses at WCCL 2026 combining MAVORIC trial data with real-world registries. Australia study (vs. vorinostat, n=67): mogamulizumab median OS not reached vs. 31.0 months, HR 0.48 (95% CI 0.30–0.76), p=0.002. Denmark study (vs. standard of care, n=209): mogamulizumab median OS not reached vs. 17.0 months, HR 0.38 (95% CI 0.25–0.59), p<0.001. ITC/survival analyses combining trial and RWD are increasingly required by payers — the team should be familiar with the methodology used here.
POTELIGEO · MF/SS · GlobeNewswire / Kyowa Kirin · June 29, 2026
The PROSPER prospective RWE study (NCT05455931; n=73: 41 MF, 32 SS) showed clinically meaningful improvements in skin itch, flaking, and redness from week 4; pain and HRQoL gains beginning at week 12; with 30% of patients reporting ≥2-point sleep improvement and 37% reporting better body temperature regulation by week 48. PRO and HRQoL data from prospective RWE studies are increasingly required for HTA submissions globally — this dataset will likely be central to KK's market access strategy.
POTELIGEO · MF/SS · EJHaem · PubMed (PMID 42359026) · June 2026
A SEER-22 database analysis (n=403 SS patients, 2000–2021) showed improving but still poor survival: median OS 48 months and 5-year OS 42.7%, with survival improving across decades. Black patients had significantly worse adjusted mortality and earlier diagnosis, highlighting persistent racial disparities. This contemporary population-level survival baseline is essential for any cost-effectiveness or comparative effectiveness models for mogamulizumab in SS.
POTELIGEO · MF/SS · ASH 2024 (Abstract 200596)
A Phase 2 open-label multicenter study presented at ASH 2024 evaluated a monthly (4-weekly) dosing schedule for mogamulizumab in MF/SS, vs. the standard weekly induction dosing. If successful, a less frequent maintenance schedule would significantly improve patient convenience and could differentiate POTELIGEO in market access discussions around administration burden — a key dimension in HEOR value dossiers for oncology.
POTELIGEO · MF/SS · JAAD International · PubMed (PMID 42328428) · May 2026
A retrospective case series (JAAD International, May 2026; DOI: 10.1016/j.jdin.2026.05.016) evaluated the sensitivity of circulating tumor DNA (ctDNA) as a monitoring biomarker in advanced MF. Note: no abstract is available via PubMed (PMID 42328428); the description is based on the published title and author-supplied keywords. While early-stage, ctDNA monitoring is an emerging theme in CTCL that could eventually influence treatment sequencing and payer evidence requirements.